AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT06590090

Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

A Phase 2 study testing Natrunix 400 mg and Methotrexate (MTX) in people with Rheumatoid Arthritis, run by XBiotech, Inc..

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Natrunix 400 mg and Methotrexate (MTX)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
108 participants
Where
No sites listed yet
Study dates
15 Jul 2026to 15 Jul 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Weight > 40 kg
  • Diagnosis of moderate to severe RA according to 2010 ACR/EULAR classification criteria.
  • Patients must be methotrexate-inadequate responders.
  • Persistent moderate to severe RA disease activity (i.e., criteria #2 above) despite ongoing treatment with MTX.
  • Meets the following minimum disease activity criteria at screening: ≥6 swollen joints (based on DAS28) and ≥6 tender joints (based on DAS28) and DAS-ESR (Erythrocyte Sedimentation Rate) > 3.2.
  • Subject must be receiving MTX treatment at a dosage of 10-25 mg/week for a minimum of 12 weeks; and be receiving a stable dose of MTX for >4 weeks preceding randomization. Subjects must also be in principle agreement to remain at the pre-randomization stable dose of MTX for the entire duration of the study. Subjects must also be willing to take a minimum of 5 mg folic acid/folinic acid per week for the duration of the study.
Show all 15Show fewer
  • Subjects must have discontinued all csDMARDs (excluding MTX) for at least 4 weeks or 5 half-lives prior to enrollment, whichever is longer.
  • Subjects taking regular NSAIDs, Acetaminophen, oral corticosteroids (<10mg/day prednisone equivalent), and inhaled corticosteroids must be on a stable dose for 2 weeks prior to enrollment.
  • Subjects must have discontinued high potency opioids (oxycodone, fentanyl, etc.) for at least 4 weeks prior to enrollment.
  • Male or female, at least 18 years of age, willing to provide informed consent, able to attend all clinic visits, comply with study-related procedures and able to understand and complete study-related questionnaires.
  • Patients must provide at least 7 consecutive days of NRS-pain data in the subject's diary prior to the baseline visit. The NRS pain diary should ideally be completed for the 7 days immediately prior to Visit 1 (when the first dose of test drug is administered). Subjects may record more than 7 days of pain records in the diary for their baseline. At least seven consecutive days of pain diary are necessary to be eligible for enrollment in the study.
  • Peripheral blood CD19+ cell count recovery to >10 cells/uL or >1% of total lymphocyte count (Required only for subjects who have received a Rituximab (or anti-CD20 biosimilar) infusion within 12 months prior to enrollment).
  • Female patients of childbearing potential must consent to undergo a serum pregnancy test at enrollment, and urine pregnancy tests at each visit after screening. Women of non-childbearing potential include those considered to have a medical history that indicates that pregnancy is not a reasonable risk, including post-menopausal women and those with a history of hysterectomy or surgically sterilized.
  • In case of female patients of childbearing potential, willingness to use one method of contraception of high efficacy during the entire study period. These methods can include but not limited to hormonal contraceptives, intrauterine devices, condoms, diaphragms, etc.
  • Males participating in this clinical research study should not get a sexual partner pregnant during their participation in this research study as the effect of the study drug on sperm is not known. Male contraception methods can include but are not limited to mechanical methods (e.g., abstinence, non-vaginal intercourse), contemporary methods comprising barrier methods (e.g., spermicide, condom, sponge, diaphragm and cervical cap) and vasectomy.

Who cannot join

  • History of treatment with Natrunix for any reason.
  • Any active, chronic, or recurrent infections. (e.g., ongoing bacterial, viral, or fungal infection).
  • Comorbid severe psychiatric illness and/or complicated social situations that would limit compliance with study requirements.
  • Patients with a positive result of TB test (QuantiFERON-TB Gold (QFT) at screening unless the patients can present a documentation of completion of TB treatment course by the local Health Department and a clear chest x-ray at enrollment.
  • Patients who have failed more than 1 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) regimen (excluding Methotrexate monotherapy) due to inefficacy at any point prior to enrollment.
  • Patients who have received any biological therapy including anakinra, rilonacept, canakinumab, adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept, tocilizumab, sarilumab, and biosimilars at any point prior to enrollment.
Show all 31Show fewer
  • Treatment with JAK inhibitors at any point prior to enrollment.
  • Patients who have received treatment with Injectable corticosteroids within 8 weeks prior to enrollment.
  • Investigational therapy administered within a time interval less than at least 5 half-lives of the investigational agent prior to the first scheduled day of dosing in this study.
  • Pregnant or breastfeeding patients.
  • Patients with current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within a year prior to enrollment.
  • Uncontrolled heart disease, including NYHA Class III or IV congestive heart failure, ventricular arrhythmia, uncontrolled blood pressure (defined as ≥ 160/100 mm Hg), or unstable angina.
  • Clinically significant laboratory abnormalities, including:
  • Hemoglobin <9.0 g/dL
  • White blood cell counts < 4000/mm3
  • Absolute neutrophil count (ANC) <1500/mm3
  • Platelet count <100,000/mm3
  • Absolute lymphocyte count (ALC) <500/mm3
  • eGFR <45 mL/min
  • Alanine Aminotransferase (ALT) >1.5x lab upper limit of normal (ULN)
  • Aspartate Aminotransferase (AST) >1.5x lab upper limit of normal (ULN)
  • Bilirubin >1.5x lab upper limit of normal (ULN)
  • Major surgery (including joint surgery) within 3 months of baseline.
  • Patients who have suffered severe trauma or fracture within 4 weeks of baseline.
  • Evidence of active hepatitis B, hepatitis C, or HIV infection.
  • Patients positive for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded.
  • Patients who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on a subsequent sample will be eligible to participate. Patients who are positive for Hepatitis C antibody and have a positive result for the HCV when the Hepatitis C RNA-PCR assay is performed on the subsequent sample will not be eligible to participate.
  • Any other concomitant disease, disorder, or condition that could interfere with the interpretation of study endpoints, or the patient's ability to participate in and complete the study, including but not limited to:
  • Coexisting diseases which are contraindicated for MTX treatment.
  • Cardiovascular, renal, pulmonary, gastrointestinal, or nervous system disorders that, in the opinion of the principal investigator and/or study medical monitor, make the patient not suitable for enrollment.
  • Concurrent autoimmune disease excluding Sjogren's syndrome secondary to rheumatoid arthritis.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Haritha Pallapotu contact

512-386-2992

hpallapotu@xbiotech.com

Norma Gonzalez contact

ngonzalez@xbiotech.com

About this study

Official title: Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate for the Treatment of Rheumatoid Arthritis

Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE).

The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.

Read the detailed description

Number of Planned Subjects: Approximately 108 subjects within 2 arms randomized 2:1 [400 mg Natrunix + MTX weekly (n=72) or placebo + MTX weekly arms (n=36)].

Study Duration: The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.

Study Design: Subjects will be randomized into the study in a 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE).

Subjects will undergo a preliminary assessment for study eligibility. Subjects who meet pre-screening requirements may then provide informed consent to acknowledge understanding of and accept enrollment into the clinical study. Subjects enrolled in the study will be taking concomitant methotrexate, have a diagnosis of moderate to severe RA according to 2010 ACR/EULAR classification criteria and have ≥6 swollen joints (based on DAS28), ≥6 tender joints (based on DAS28) and DAS-ESR > 3.2.

Being tested
Natrunix 400 mg, Placebo, Methotrexate (MTX)
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Natrunix 400 mgBiological

    Also called methotrexate

    The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human.

    Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0.

  • PlaceboDrug

    Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product

  • Methotrexate (MTX)Drug

    Methotrexate may be administered in pill form by mouth, as liquid by mouth, or by subcutaneous injection.Subjects enrolled in this study should be receiving a stable minimum weekly dose of 10mg. Weekly methotrexate should not exceed 25 mg/week.

Study groups in NCT06590090
Study groupRoleWhat they receive
400mg Natrunix + MTX weeklyExperimentalSubjects will receive 400mg Natrunix and MTX weekly
Receives: Biological: Natrunix 400 mg; Drug: Methotrexate (MTX)
Placebo+ MTX weeklyExperimentalSubjects will receive placebo and MTX weekly
Receives: Drug: Placebo; Drug: Methotrexate (MTX)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ACR 20 response

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 14 weeks from baseline

Secondary outcomes (34)

  1. ACR 50 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 14 weeks from baseline

  2. Mean change in number of swollen and tender joints based on 66/68-joint count

    Subject's tender and swollen joint will be counted by investigators

    Measured: at 14 weeks from baseline

  3. Mean change in NRS-pain score

    Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain

    Measured: at 14 weeks from baseline

  4. ACR 70 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  5. ACR 20 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 2, 4, 8 and 12 weeks from baseline

  6. ACR 50 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 2, 4, 8 and 12 weeks from baseline

  7. Mean change in HAQ-DI score

    HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI): This questionnaire is used in this study which has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities subjects will be assessed on. In each section, 0 represents without any difficulty and 3 represents task cannot be done at all. In each section, if one question is scored 1 and another 2, then the score for the section is 2. If an aid or device is used or if help is required from another individual, then the minimum score for that section is 2. If the section score is already 2 or more then no modification is made. If any task is not applicable, it can be left blank by the subject.

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  8. Mean change in NRS-pain score

    Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain

    Measured: at 2, 4, 8 and 12 weeks from baseline

  9. Mean change in RAPID-3 score

    The RAPID3 (Routine Assessment of Patient Index Data 3) is an index of data set measures to assess disease severity. Each measure is scored 0 to 10, for a total of 30. Higher RAPID3 scores correlate with higher disease severity (>12 = high; 6.1-12 = moderate; 3.1-6 = low; < 3 = remission).

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  10. Mean change in the PGA score

    A patient global assessment (PGA) score is a single question with a 0 to 10 response. Higher scores represent a higher level of disease activity or a worse global health.

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  11. Mean change in the EGA score

    The evaluator global assessment (EGA) score is a single question used to assess how well a patient is doing regarding the status of a disease. This is scored 0-10, higher scores represent worse activity.

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  12. Mean change in number of swollen and tender joints based on 66/68-joint count

    Subject's tender and swollen joint will be counted by investigators

    Measured: at 2, 4, 8, and 12 weeks from baseline

  13. Mean change in the CDAI score

    The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity, it is based on the count of swollen/tender joint count of 28 joints along with patient and evaluator global assessments. The CDAI has a range of 0 -76 and can be classified as: remission (≤2.8), low disease activity (2.9-10), moderate disease activity (10.1-22), and high disease activity (>22).

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  14. Mean change in DAS28-ESR score

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease:

    <2.6: Remission 2.6-3.2: Low disease activity 3.2-5.1: Moderate disease activity >5.1: High disease activity

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  15. Percentage of patients with Low Disease Activity (DAS-ESR <3.2; CDAI > 2.8 & ≤ 10)

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease.

    The Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis determines severity of rheumatoid arthritis

    Measured: at 2, 4, 8, 12 and 14 weeks from baseline

  16. Occurence of AEs and SAEs in subjects during the trial

    Subjects will be monitored for any adverse events or serious adverse reactions due to study drug

    Measured: until 28 weeks from baseline

  17. Any abnormality in Physical examination will be monitored

    Physical examination is the process of evaluating objective anatomic findings through the use of observation, palpation, percussion, and auscultation.

    Measured: until 28 weeks from baseline

  18. Any clinically significant changes in vital signs from normality will be assessed

    Vital signs are measurements of the body's most basic functions, such as breathing rate, heart rate, body temperature, and blood pressure.

    Measured: until 28 weeks from baseline

  19. Any abnormal laboratory tests will be monitored

    Laboratory test is a medical procedure that involves testing a sample of blood, urine, or other substance from the body.

    Measured: until 28 weeks from baseline

  20. ACR 20 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 22 and 28 OLE weeks

  21. ACR 50 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 22 and 28 OLE weeks

  22. ACR 70 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Measured: at 22 and 28 OLE weeks

  23. Mean change in number of swollen and tender joints based on 66/68-joint count

    Subject's tender and swollen joint will be counted by investigators

    Measured: at 22 and 28 OLE weeks

  24. Mean change in NRS-pain score

    Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain

    Measured: at 22 and 28 OLE weeks

  25. Mean change in HAQ-DI score

    HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI): This questionnaire is used in this study which has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities subjects will be assessed on. In each section, 0 represents without any difficulty and 3 represents task cannot be done at all. In each section, if one question is scored 1 and another 2, then the score for the section is 2. If an aid or device is used or if help is required from another individual, then the minimum score for that section is 2. If the section score is already 2 or more then no modification is made. If any task is not applicable, it can be left blank by the subject.

    Measured: at 22 and 28 OLE weeks

  26. Mean change in RAPID-3 score

    The RAPID3 (Routine Assessment of Patient Index Data 3) is an index of data set measures to assess disease severity. Each measure is scored 0 to 10, for a total of 30. Higher RAPID3 scores correlate with higher disease severity (>12 = high; 6.1-12 = moderate; 3.1-6 = low; < 3 = remission).

    Measured: at 22 and 28 OLE weeks

  27. Mean change in the PGA score

    A patient global assessment (PGA) score is a single question with a 0 to 10 response. Higher scores represent a higher level of disease activity or a worse global health.

    Measured: at 22 and 28 OLE weeks

  28. Mean change in the EGA score

    The evaluator global assessment (EGA) score is a single question used to assess how well a patient is doing regarding the status of a disease. This is scored 0-10, higher scores represent worse activity.

    Measured: at 22 and 28 OLE weeks

  29. Mean change in the CDAI score

    The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity, it is based on the count of swollen/tender joint count of 28 joints along with patient and evaluator global assessments. The CDAI has a range of 0 -76 and can be classified as: remission (≤2.8), low disease activity (2.9-10), moderate disease activity (10.1-22), and high disease activity (>22).

    Measured: at 22 and 28 OLE weeks

  30. Mean change in DAS28-ESR score

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease:

    <2.6: Remission 2.6-3.2: Low disease activity 3.2-5.1: Moderate disease activity >5.1: High disease activity

    Measured: at 22 and 28 OLE weeks

  31. Percentage of patients with Low Disease Activity (DAS-ESR <3.2; CDAI > 2.8 & ≤ 10)

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease.

    The Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis determines severity of rheumatoid arthritis

    Measured: at 22 and 28 OLE weeks

  32. Assessment of Maximum Plasma Concentration

    Blood samples will be collected from subjects. Maximum Plasma Concentration (Cmax) measurement of Natrunix will be performed in all enrolled participants.

    Measured: at baseline (pre-treatment) until week 14

  33. Number of participants with Anti-Drug Antibodies

    Blood samples will also be used to test for the presence of treatment emergent anti-drug antibodies (ADA) against Natrunix. XBiotech has developed an ELISA method to perform quantitative and qualitative measurements of ADA.

    Measured: at baseline (pre-treatment) until week 14

  34. ECG QTc interval

    An electrocardiogram (ECG or EKG) is a non-invasive test that records the cardiac electrical activity. QTc(ms) value will be collected along with a clinical interpretation. A normal QTc interval on an ECG, is generally considered to be between 350 and 450 milliseconds (ms) for men and 360 to 460 ms for women. Any abnormalities in ECG will be recorded during study from baseline.

    Measured: until 28 weeks from baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2024
  2. Study start15 Jul 2026 (estimated)
  3. Primary completion15 Jan 2027 (estimated)
  4. Study completion15 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
108 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06590090
Sponsor's protocol ID
PT067
Status last verified
Dec 2025
First submitted
22 Aug 2024
Last updated
9 Dec 2025
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Natrunix 400 mg and Methotrexate (MTX) in people with Rheumatoid Arthritis, run by XBiotech, Inc..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Haritha Pallapotu (512-386-2992, hpallapotu@xbiotech.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ACR 20 response (time frame: at 14 weeks from baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06590090.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in